Inmune Bio Stock Analysis

INmune Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. INmune Bio recorded a loss per share of 2.11. The entity had not issued any dividends in recent years. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about INmune Bio call David MBA at 858 964 3720 or check out https://www.inmunebio.com.

INmune Bio Investment Alerts

INmune Largest EPS Surprises

View All Earnings Estimates

INmune Stock Institutional Investors

Note, although INmune Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

INmune Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.27 M.

INmune Profitablity

Management Efficiency

INmune Bio has return on total asset (ROA) of (0.5059) % which means that it has lost $0.5059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5577) %, meaning that it created substantial loss on money invested by shareholders. INmune Bio's management efficiency ratios could be used to measure how well INmune Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of February 2, 2026, Return On Tangible Assets is expected to decline to -1.73. The current year's Return On Capital Employed is expected to grow to -1.44. At present, INmune Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 26.9 M, whereas Total Assets are forecasted to decline to about 41.8 M.

Technical Drivers

As of the 2nd of February, INmune Bio retains the Risk Adjusted Performance of (0.01), standard deviation of 4.62, and Market Risk Adjusted Performance of (0.07). INmune Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

INmune Bio Price Movement Analysis

INmune Bio Insider Trading Activities

INmune Bio Outstanding Bonds

INmune Bio Predictive Daily Indicators

INmune Bio Forecast Models

INmune Bio's time-series forecasting models are one of many INmune Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary INmune Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

INmune Bio Bond Ratings

INmune Bio financial ratings play a critical role in determining how much INmune Bio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for INmune Bio's borrowing costs.

INmune Bio Debt to Cash Allocation

INmune Bio currently holds 384 K in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. INmune Bio has a current ratio of 30.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about INmune Bio's use of debt, we should always consider it together with its cash and equity.

INmune Bio Total Assets Over Time

INmune Bio Assets Financed by Debt

The debt-to-assets ratio shows the degree to which INmune Bio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

INmune Bio Debt Ratio

1.06

It appears most of the INmune Bio's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the INmune Bio's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of INmune Bio, which in turn will lower the firm's financial flexibility.

INmune Bio Corporate Bonds Issued

INmune Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how INmune Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling INmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as INmune Bio. By using and applying INmune Stock analysis, traders can create a robust methodology for identifying INmune entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. INmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. INmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

INmune Bio stock analysis indicators help investors evaluate how INmune Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading INmune Bio shares will generate the highest return on investment. By understating and applying INmune Bio stock analysis, traders can identify INmune Bio position entry and exit signals to maximize returns.

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.